The Differential Expression of CD47 May Be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Apr 18

PMID 35433462

Authors

Xiao Yan

Binbin Lai

Xuyan Zhou

Shujun Yang

Qunfang Ge

Miao Zhou

Cong Shi

Zhijuan Xu

Guifang Ouyang

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndrome (MDS) can lead to the development of peripheral blood cytopenia and abnormal cell morphology. MDS has the potential to evolve into AML and can lead to reduced survival. CD47, a member of the immunoglobulin family, is one molecule that is overexpressed in a variety of cancer cells and is associated with clinical features and poor prognosis in a variety of malignancies. In this study, we analyzed the expression and function of CD47 in MDS and AML, and further analyzed its role in other tumors. Our analysis revealed significantly low CD47 expression in MDS and significantly high expression in AML. Further analysis of the function or pathway of CD47 from different perspectives identified a relationship to the immune response, cell growth, and other related functions or pathways. The relationship between CD47 and other tumors was analyzed from four aspects: DNA methyltransferase, TMB, MSI, and tumor cell stemness. Changes in gene expression levels have a known association with aberrant DNA methylation, and this methylation is the main mechanism of tumor suppressor gene silencing and clonal variation during the evolution of MDS to AML. Taken together, our findings support the hypothesis that the differential expression of CD47 might be related to the transformation of MDS to AML.

Citing Articles

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).

Wu F, Pang H, Li F, Hua M, Song C, Tang J Oncol Lett. 2024; 27(6):256.

PMID: 38646501 PMC: 11027102. DOI: 10.3892/ol.2024.14389.

Has-miR-199a-3p/RELA/SCD inhibits immune checkpoints in AMD and promotes macrophage-mediated inflammation and pathological angiogenesis through lipid metabolism pathway: A computational analysis.

Jiang J, Wang S, Li Y, Wang Y, Liao R PLoS One. 2024; 19(4):e0297849.

PMID: 38625951 PMC: 11020405. DOI: 10.1371/journal.pone.0297849.

GPX4 is a potential diagnostic and therapeutic biomarker associated with diffuse large B lymphoma cell proliferation and B cell immune infiltration.

Chen C, Li T, Li Y, Chen Z, Shi P, Li Y Heliyon. 2024; 10(3):e24857.

PMID: 38333875 PMC: 10850411. DOI: 10.1016/j.heliyon.2024.e24857.

TLR3 agonism augments CD47 inhibition in acute myeloid leukemia.

Ramsey H, Gorska A, Smith B, Monteith A, Fuller L, Arrate M Haematologica. 2023; 109(7):2111-2121.

PMID: 38152031 PMC: 11215363. DOI: 10.3324/haematol.2023.283850.

MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.

Zheng Z, Chen X, Zhang Y, Ren F, Ma Y Int J Oncol. 2023; 63(6).

PMID: 37921060 PMC: 10631768. DOI: 10.3892/ijo.2023.5588.

References

Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian H . Myelodysplastic syndrome is not merely "preleukemia". Blood. 2002; 100(3):791-8. DOI: 10.1182/blood.v100.3.791. View

Wang L, Choi Y, Hua X, Shin Y, Song Y, Youn S . Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod Pathol. 2006; 19(5):675-83. DOI: 10.1038/modpathol.3800573. View

Tawana K, Drazer M, Churpek J . Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. Leukemia. 2018; 32(7):1482-1492. DOI: 10.1038/s41375-018-0051-y. View

Dexheimer G, Alves J, Reckziegel L, Lazzaretti G, Abujamra A . DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome. Dis Markers. 2017; 2017:5472893. PMC: 5606093. DOI: 10.1155/2017/5472893. View

Tsujioka T, Yokoi A, Uesugi M, Kishimoto M, Tochigi A, Suemori S . Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines. Exp Hematol. 2012; 41(2):189-97. DOI: 10.1016/j.exphem.2012.10.006. View

Franco R, Schoneveld O, Georgakilas A, Panayiotidis M . Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008; 266(1):6-11. DOI: 10.1016/j.canlet.2008.02.026. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Cortes J, Heidel F, Hellmann A, Fiedler W, Smith B, Robak T . Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018; 33(2):379-389. PMC: 6365492. DOI: 10.1038/s41375-018-0312-9. View

Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini E . SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. J Hematol Oncol. 2021; 14(1):155. PMC: 8477557. DOI: 10.1186/s13045-021-01163-6. View

10.

Kim H, Jee S, Kim Y, Sim J, Bang S, Son H . Correlation of CD47 Expression with Adverse Clinicopathologic Features and an Unfavorable Prognosis in Colorectal Adenocarcinoma. Diagnostics (Basel). 2021; 11(4). PMC: 8068136. DOI: 10.3390/diagnostics11040668. View

11.

Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M . Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012; 2(5):508-28. PMC: 3433102. View

12.

Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernandez-Pedro N, Cardona A, Cabrera-Miranda L . Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020; 9(7):2390-2402. PMC: 7131854. DOI: 10.1002/cam4.2882. View

13.

Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J . The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 2000; 10(12):1419-32. DOI: 10.1023/a:1008375931236. View

14.

Greenberg P, Stone R, Al-Kali A, Barta S, Bejar R, Bennett J . Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(1):60-87. DOI: 10.6004/jnccn.2017.0007. View

15.

Larsson C, Cote G, Quintas-Cardama A . The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res. 2013; 11(8):815-27. PMC: 4123851. DOI: 10.1158/1541-7786.MCR-12-0695. View

16.

Yu J, Li Y, Li T, Li Y, Xing H, Sun H . Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020; 9:2. PMC: 6945703. DOI: 10.1186/s40164-019-0158-5. View

17.

Weinberg O, Hasserjian R . The current approach to the diagnosis of myelodysplastic syndromes. Semin Hematol. 2018; 56(1):15-21. DOI: 10.1053/j.seminhematol.2018.05.015. View

18.

Bewersdorf J, Carraway H, Prebet T . Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol. 2020; 11:2040620720955006. PMC: 7675905. DOI: 10.1177/2040620720955006. View

19.

Chao M, Weissman I, Majeti R . The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012; 24(2):225-32. PMC: 3319521. DOI: 10.1016/j.coi.2012.01.010. View

20.

Shim S, Lee H, Park O, Shin H, Lee K, Lee H . Dynamic changes in DNA methylation occur in TE regions and affect cell proliferation during leaf-to-callus transition in Arabidopsis. Epigenetics. 2021; 17(1):41-58. PMC: 8812807. DOI: 10.1080/15592294.2021.1872927. View